G9pharma co., LTD announced a private placement of round 15 non-guaranteed private equity convertible bonds for gross proceeds of KRW 10,000,000,000, round 14 unregistered non-guaranteed private equity convertible bonds for the gross proceeds of KRW 10,000,000,000 and 5,159,071 common shares at a price of KRW 1,163 per share for gross proceeds of KRW 5,999,999,573, for aggregate gross proceeds of KRW 25,999,999,573 on April 22, 2021. The transaction will include participation from Unibada Co., Ltd. for round 15 non-guaranteed private equity convertible bonds for gross proceeds of KRW 10,000,000,000 and Medi Forum Co.,Ltd. for 5,159,071 shares and Tobico Bio Co., Ltd. for round 14 unregistered non-guaranteed private equity convertible bonds for gross proceeds of KRW 10,000,000,000. The bonds do not carry any interest and yield to maturity. The bonds will mature on June 03, 2024. Both round 15 non-guaranteed private equity convertible bonds and round 14 unregistered non-guaranteed private equity convertible bonds are fully convertible into 7,107,320 shares each, at a fixed conversion price of KRW 1,407 per share, representing 9.34% stake respectively in the company. The bonds are convertible from June 03, 2022 to May 03, 2024. The subscription date of bonds is April 26, 2021 and payment date of bonds is June 03, 2021. The share will be issued at a premium. The securities issued in the transaction carry a lock period of 1 year. The shares will be issued through third party allotment method. The payment date of shares is June 2, 2021. The transaction has been approved by the board of directors of the company.